Comparative Pharmacology
Head-to-head clinical analysis: AMIKACIN SULFATE versus HUMATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIKACIN SULFATE versus HUMATIN.
AMIKACIN SULFATE vs HUMATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.
Aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
15 mg/kg/day IV or IM divided every 8-12 hours; typical adult dose 500 mg IV/IM every 12 hours or 7.5 mg/kg every 12 hours.
15-25 mg/kg/day orally in 4 divided doses for hepatic coma; 50 mg/kg/day orally in 4 divided doses for infectious diarrhea, max 4 g/day.
None Documented
None Documented
Terminal: 2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; neonates 4-8 hours.
2-3 hours (serum half-life of absorbed fraction); clinically negligible due to minimal systemic absorption
Renal: >90% unchanged via glomerular filtration. Biliary/fecal: <1%.
Primarily unchanged in feces (~90%); small amount absorbed is excreted renally as unchanged drug (~1%)
Category D/X
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic